The US Food and Drug Administration has approved Rhone-Poulenc Rorer's Lovenox (enoxaparin sodium) for the prevention of deep vein thrombosis, which may lead to pulmonary embolism, following knee replacement surgery.
Patients undergoing hip and knee replacements are at risk of developing post-operative venous thromboembolic disease. "While the orthopedic community has experienced the benefits of enoxaparin in hip replacement, we now have proof that this method will provide the same benefits for use after knee replacement surgery," said Robert Fitzgerald, professor and chairman of orthopedic surgery at Wayne State School of Medicine.
Lovenox is approved in 47 countries and is R-PR's best selling product, with sales exceeding $200 million a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze